Stay updated on Pembrolizumab Combo in Stage III NSCLC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Combo in Stage III NSCLC Clinical Trial page.

Latest updates to the Pembrolizumab Combo in Stage III NSCLC Clinical Trial page
- Check5 days agoChange DetectedA sitewide notice about NIH terminology changes was added above the ClinicalTrials.gov page, and the displayed site revision changed from v3.7.1 to v3.7.2.SummaryDifference1%

- Check12 days agoNo Change Detected
- Check19 days agoChange DetectedThe site footer revision changes from v3.7.0 to v3.7.1; the page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check33 days agoChange DetectedSponsor-related content and external data-sharing links were removed from the page, including Merck branding, IPD sharing URLs, and references to study documents.SummaryDifference20%

- Check40 days agoChange DetectedRevision: v3.7.0 is now shown on the page, replacing the previous Revision: v3.6.6. This indicates an updated page revision of the study details.SummaryDifference0.0%

- Check54 days agoChange DetectedThe page's revision tag was updated from v3.6.5 to v3.6.6, signaling a backend/software update rather than changes to the study information presented.SummaryDifference0.0%

- Check61 days agoChange DetectedA new NIH funding entry for 2018 was added to the study's identifiers. This updates the record to reflect U.S. NIH support for KEYNOTE-799.SummaryDifference0.0%

Stay in the know with updates to Pembrolizumab Combo in Stage III NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Combo in Stage III NSCLC Clinical Trial page.